BOLD

MKT CAP:$34M

Boundless Bio, Inc.

Market Cap

$34M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$1.52+$0.30 (+24.59%)

Apr 23, 2026

Company Details

Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. Its lead product candidate is BBI-355, an oral inhi...

CEO

Zachary Hornby

IPO Date

Jul 20, 2016

Website

boundlessbio.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$58M

EPS (Diluted)

-$2.61

Free Cash Flow

-$47M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

Q1 2026

May 8, 2026

PENDING

FY 2025

Mar 9, 2026

$0EPS -$2.60

Q4 2025

Mar 9, 2026

$0EPS -$0.58

Q3 2025

Nov 5, 2025

$0EPS -$0.62

Q2 2025

Aug 5, 2025

$0EPS -$0.70

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q2 19	$0	$0	-$99M
Q3 19	$0	$0	-$147M
Q3 22	$0	$0	-$13M
Q4 22	$0	$0	-$12M
Q1 23	$0	$0	-$12M
Q2 23	$0	$0	-$14M
Q3 23	$0	$0	-$15M
Q4 23	$0	$0	-$14M
Q1 24	$0	$0	-$17M
Q2 24	$0	-$265.0K	-$19M
Q3 24	$0	$0	-$19M
Q4 24	$0	$0	-$18M
Q1 25	$0	$0	-$17M
Q2 25	$0	-$317.0K	-$17M
Q3 25	$0	-$310.0K	-$15M
Q4 25	$0	-$307.0K	-$14M

Operating Cash Flow

Quarter	Operating CF	Free CF
Q2 19	-$41M	-$45M
Q3 19	-$36M	-$40M
Q3 22	-$11M	-$11M
Q4 22	-$10M	-$10M
Q1 23	-$12M	-$12M
Q2 23	-$11M	-$11M
Q3 23	-$12M	-$12M
Q4 23	-$12M	-$12M
Q1 24	-$16M	-$16M
Q2 24	-$16M	-$18M
Q3 24	-$13M	-$14M
Q4 24	-$16M	-$16M
Q1 25	-$15M	-$15M
Q2 25	-$12M	-$12M
Q3 25	-$10M	-$10M
Q4 25	-$10M	-$11M

Capital Expenditures

Quarter	CapEx
Q2 19	$4M
Q3 19	$4M
Q3 22	$114.0K
Q4 22	$39.0K
Q1 23	$86.0K
Q2 23	$128.0K
Q3 23	$151.0K
Q4 23	$268.0K
Q1 24	$83.0K
Q2 24	$2M
Q3 24	$483.0K
Q4 24	$466.0K
Q1 25	$59.0K
Q2 25	$48.0K
Q3 25	$15.0K
Q4 25	$424.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q2 19	—	+67.5%
Q3 19	—	+51.6%
Q3 22	—	-90.1%
Q4 22	—	-76.7%
Q1 23	—	-87.8%
Q2 23	—	-90.5%
Q3 23	—	+12.8%
Q4 23	—	+14.3%
Q1 24	—	+39.7%
Q2 24	—	+38.9%
Q3 24	—	+25.2%
Q4 24	—	+32.5%
Q1 25	—	+2.7%
Q2 25	—	-12.0%
Q3 25	—	-19.1%
Q4 25	—	-23.4%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q2 19	$6M	—
Q3 19	$6M	—
Q3 22	$596.0K	—
Q4 22	$592.0K	—
Q1 23	$615.0K	—
Q2 23	$927.0K	—
Q3 23	$883.0K	—
Q4 23	$911.0K	—
Q1 24	$1M	—
Q2 24	$2M	—
Q3 24	$2M	—
Q4 24	$2M	—
Q1 25	$2M	—
Q2 25	$2M	—
Q3 25	$1M	—
Q4 25	$1M	—

OpEx Breakdown

Quarter	R&D	G&A
Q2 19	$37M	$10M
Q3 19	$38M	$10M
Q3 22	$11M	$2M
Q4 22	$10M	$2M
Q1 23	$10M	$3M
Q2 23	$11M	$3M
Q3 23	$12M	$3M
Q4 23	$10M	$3M
Q1 24	$13M	$4M
Q2 24	$14M	$5M
Q3 24	$14M	$5M
Q4 24	$13M	$5M
Q1 25	$12M	$5M
Q2 25	$12M	$5M
Q3 25	$10M	$4M
Q4 25	$10M	$4M

War Chest

Quarter	Cash	Short-term Investments	Total
Q4 18	$144M	$270M	$414M
Q1 19	$133M	$242M	$375M
Q2 19	$99M	$280M	$379M
Q3 19	$64M	$288M	$351M
Q4 22	$11M	$56M	$67M
Q2 23	$41M	$103M	$144M
Q3 23	$21M	$112M	$133M
Q4 23	$24M	$97M	$121M
Q1 24	$25M	$80M	$105M
Q2 24	$31M	$148M	$179M
Q3 24	$40M	$127M	$167M
Q4 24	$27M	$126M	$152M
Q1 25	$15M	$123M	$138M
Q2 25	$15M	$112M	$127M
Q3 25	$15M	$103M	$118M
Q4 25	$18M	$90M	$108M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q2 19	44M	0.0%	0.0%
Q3 19	45M	+1.2%	+1.2%
Q3 22	22M	-50.1%	-49.5%
Q4 22	22M	0.0%	-49.5%
Q1 23	22M	0.0%	-49.5%
Q2 23	22M	0.0%	-50.1%
Q3 23	22M	0.0%	0.0%
Q4 23	22M	0.0%	0.0%
Q1 24	22M	0.0%	0.0%
Q2 24	22M	-1.0%	-1.0%
Q3 24	22M	+1.0%	+0.1%
Q4 24	17M	-23.7%	-23.6%
Q1 25	22M	+31.3%	+0.3%
Q2 25	22M	+0.3%	+1.5%
Q3 25	22M	+0.1%	+0.6%
Q4 25	22M	-0.1%	+31.7%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q2 19	—	—
Q3 19	—	—
Q3 22	—	—
Q4 22	—	—
Q1 23	—	—
Q2 23	—	—
Q3 23	—	—
Q4 23	—	—
Q1 24	—	—
Q2 24	—	—
Q3 24	—	—
Q4 24	$0	200K
Q1 25	$0	200K
Q2 25	$0	200K
Q3 25	$0	200K
Q4 25	$0	200K

Revenue / Employee